Sema4_Logo2021_Primary_Gradient.png
Sema4 to Participate at Two Investor Conferences in June 2022
May 26, 2022 08:00 ET | Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2022 16:05 ET | Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
May 02, 2022 07:45 ET | Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4_Logo2021_Primary_Gradient.png
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 26, 2022 16:05 ET | Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4_Logo2021_Primary_Gradient.png
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
February 22, 2022 16:05 ET | Sema4
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
February 22, 2022 08:00 ET | Sema4
STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a...
Sema.jpg
Sema4 to Participate at Three Upcoming Investor Conferences in November
November 03, 2021 09:15 ET | Sema4
STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...
Sema.jpg
Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
October 19, 2021 16:05 ET | Sema4
STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Gustavo Stolovitzsky
Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer
September 13, 2021 08:00 ET | Sema4
STAMFORD, Conn., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the appointment of Gustavo Stolovitzky, PhD, to the...
Sema.jpg
Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health
September 09, 2021 08:00 ET | Sema4
STAMFORD, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the launch of Sema4 Elements™, a portfolio of...